Compare ARVN & SUPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | SUPV |
|---|---|---|
| Founded | 2015 | 1887 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 703.9M |
| IPO Year | 2018 | 2015 |
| Metric | ARVN | SUPV |
|---|---|---|
| Price | $6.82 | $7.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 5 |
| Target Price | ★ $13.93 | $11.80 |
| AVG Volume (30 Days) | ★ 772.6K | 541.9K |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $12.76 | $32.97 |
| Revenue Next Year | N/A | $20.17 |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.80 | $5.83 |
| 52 Week High | $14.22 | $13.55 |
| Indicator | ARVN | SUPV |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 35.52 |
| Support Level | N/A | $6.72 |
| Resistance Level | $8.52 | $7.59 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 8.61 | 30.46 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.